HGH Fragment 176-191 — C-terminal GH fragment in metabolic research

HGH Fragment 176-191 is a short peptide corresponding to the terminal segment of the human growth hormone (GH, somatotropin) molecule — specifically amino acids from position 176 to 191 of its chain. The full GH molecule comprises 191 amino acid residues; the compound discussed here is its C-terminal fragment, that is, one of the "Lego bricks" that make up the larger protein. It became a subject of scientific interest because it allows a precise research question to be posed: whether the metabolic activity of growth hormone can be separated from its action on growth. It is a model example of the "screwdriver, not a hammer" approach — instead of studying the whole, multifunctional molecule, a single, isolated fragment is analysed.

Mechanism in brief

Full growth hormone acts like a key fitting a lock — the GH receptor (GHR). The binding of GH to the receptor triggers the JAK2–STAT5 signalling cascade, leading to the production of IGF-1 in the liver, i.e. the so-called growth axis responsible for the anabolic and growth component. The C-terminal region of the molecule, to which the 176-191 fragment belongs, is in the literature associated with a distinct, metabolic activity concerning lipids. In experimental models this fragment does not reproduce the "growth" key–lock binding to the GH receptor in the same way as the full molecule. Because of this it serves as a tool for studying the hypothesis that lipid metabolism pathways can be considered in isolation from the IGF-1 axis.

What is being studied

Below are the areas described in the literature, each assigned to a model level and a named pathway. All of them concern experimental systems, not effects in humans.

• Activity in adipocytes (cell lines, e.g. 3T3-L1; rodent models) — analysis of the influence of the C-terminal region on lipid metabolism pathways in fat cells, in isolation from GH receptor signalling.
• Separation of the metabolic component from the growth component (animal models) — investigation of whether the fragment retains metabolic activity without triggering the JAK2–STAT5 cascade and the IGF-1 axis responsible for growth.
• Enzymes and pathways of lipid turnover (animal models) — observations concerning processes such as beta-oxidation and the activity of lipolytic enzymes at the level of adipose tissue in experimental systems.
• Profile of influence on carbohydrate metabolism (animal models) — investigation of whether the fragment, unlike full GH, does not induce the diabetogenic (glycaemia-raising) action of somatotropin in the model.

Origin and historical context

The 176-191 fragment derives from research on the structure–function relationship of growth hormone, conducted since the 1990s. Scientists sought to determine which regions of the 191-amino-acid GH molecule are responsible for its individual biological activities. Work on the so-called lipolytic domain of growth hormone — including Australian teams associated, among others, with Monash University — pointed to the C-terminal region as an area linked with lipid metabolism in animal models. From the same research current derives the related, modified analogue AOD-9604 (a tyrosine residue was added at the end of the 176-191 fragment), which was later developed as a separate research molecule. The 176-191 fragment thus remains historically and structurally connected with this line of research on the "metabolic" part of GH.

Research specification

The material is supplied in the form of a lyophilisate (powder after lyophilisation), intended exclusively for laboratory applications. The quality standard is purity determination by the HPLC method — liquid chromatography serves to confirm the identity and purity of the peptide, without formulating any promises as to its action. Detailed physicochemical data, including the CAS number, molecular weight and handling conditions, are found in the safety data sheet (COA/SDS) available in the safety data sheets section. A peptide lyophilisate is stored in accordance with the recommendations for the given substance; storage parameters are provided in the product documentation.

Level of evidence

Data concerning the 176-191 fragment come primarily from in vitro studies (including adipocyte lines) and from animal models (rodents). For the 176-191 fragment itself, data from controlled clinical trials in humans are limited or absent, and observations from experimental models do not automatically translate to humans. The entire area of separating the metabolic component from the growth component of the GH molecule remains a scientific hypothesis that requires further research. Every described effect should be read as an observation assigned to a specific model and pathway, not as a property confirmed in humans.

Disclaimer: For research purposes only. Not for consumption by humans or animals.